DE60227268D1 - Knockout-mutante von vaccinia-virus und verwendung davon - Google Patents

Knockout-mutante von vaccinia-virus und verwendung davon

Info

Publication number
DE60227268D1
DE60227268D1 DE60227268T DE60227268T DE60227268D1 DE 60227268 D1 DE60227268 D1 DE 60227268D1 DE 60227268 T DE60227268 T DE 60227268T DE 60227268 T DE60227268 T DE 60227268T DE 60227268 D1 DE60227268 D1 DE 60227268D1
Authority
DE
Germany
Prior art keywords
mva
viruses
mutant
vaccinia virus
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60227268T
Other languages
English (en)
Inventor
Volker Erfle
Gerd Sutter
Simone Hornemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Application granted granted Critical
Publication of DE60227268D1 publication Critical patent/DE60227268D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60227268T 2001-09-11 2002-09-11 Knockout-mutante von vaccinia-virus und verwendung davon Expired - Lifetime DE60227268D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10144664A DE10144664B4 (de) 2001-09-11 2001-09-11 Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
PCT/EP2002/010199 WO2003023040A2 (en) 2001-09-11 2002-09-11 Vaccinia virus mva-e3l-knockout-mutants and use thereof

Publications (1)

Publication Number Publication Date
DE60227268D1 true DE60227268D1 (de) 2008-08-07

Family

ID=7698583

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10144664A Expired - Fee Related DE10144664B4 (de) 2001-09-11 2001-09-11 Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
DE60227268T Expired - Lifetime DE60227268D1 (de) 2001-09-11 2002-09-11 Knockout-mutante von vaccinia-virus und verwendung davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10144664A Expired - Fee Related DE10144664B4 (de) 2001-09-11 2001-09-11 Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon

Country Status (9)

Country Link
US (1) US7049145B2 (de)
EP (1) EP1425404B1 (de)
JP (1) JP4406561B2 (de)
AT (1) ATE399210T1 (de)
AU (1) AU2002337083A1 (de)
CA (1) CA2459754C (de)
DE (2) DE10144664B4 (de)
DK (1) DK1425404T3 (de)
WO (1) WO2003023040A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
EP1678292A4 (de) * 2003-09-18 2008-05-07 Univ Emory Verbesserte mva-impfstoffe
JP4606838B2 (ja) * 2004-10-20 2011-01-05 富士フイルム株式会社 電子内視鏡装置
EP2023954B1 (de) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunologische zusammensetzung
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
WO2012050125A1 (ja) 2010-10-14 2012-04-19 味の素株式会社 モナティンの製造方法
FR2969497B1 (fr) * 2010-12-27 2013-06-28 Ceva Sante Animale Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants.
JP6569209B2 (ja) * 2014-01-07 2019-09-04 ソニー株式会社 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) * 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
US10842835B2 (en) 2016-05-25 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
EP3621646A4 (de) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center Mutanten des vaccinia-virus für die krebsimmuntherapie
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6287570B1 (en) * 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
WO2000073487A1 (en) * 1999-05-27 2000-12-07 Arizona Board Of Regents Novel viral vectors having enhanced effectiveness with dramatically reduced virulence
CN100587923C (zh) 2005-09-22 2010-02-03 东京毅力科创株式会社 选择性等离子体处理方法和等离子体处理装置

Also Published As

Publication number Publication date
AU2002337083A1 (en) 2003-03-24
WO2003023040A2 (en) 2003-03-20
US20050028226A1 (en) 2005-02-03
DE10144664A1 (de) 2003-03-27
DK1425404T3 (da) 2008-10-06
CA2459754A1 (en) 2003-03-20
JP4406561B2 (ja) 2010-01-27
DE10144664B4 (de) 2005-06-09
JP2005502360A (ja) 2005-01-27
CA2459754C (en) 2011-05-10
ATE399210T1 (de) 2008-07-15
WO2003023040A3 (en) 2003-11-27
EP1425404B1 (de) 2008-06-25
EP1425404A2 (de) 2004-06-09
US7049145B2 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
DE60227268D1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
DE122011100037I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie.
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
DE60224843D1 (de) Herstellung von viren, virusisolaten, und impfstoffen
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
UA85379C2 (ru) Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы
IL168374A (en) Vaccines against west nile virus
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
ATE403005T1 (de) Rekombinantes mva und verfahren zur erzeugung davon
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE455854T1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
DE60231970D1 (de) Neurovirulenter stamm des west-nile-virus und anwendungen davon
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
WO2004035808A3 (en) Method for detecting viral inactivating agents
SE0002498D0 (sv) Papillomavirus vaccine
WO2002078621A3 (en) Replication-competent recombinant virus and methods of use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition